
Tykerb
Brand for: Lapatinib
My Prescription
Payment
Select pharmacy




$1,969.38
Print or send this coupon to your phone
About Tykerb
Drug Details
Lapatinib, also known by the brand name Tykerb, is an oral medication prescribed for certain types of breast cancer that have spread to other parts of the body, specifically HER2-positive and HR-positive, HER2-positive metastatic breast cancer. It functions as a tyrosine kinase inhibitor by blocking the activity of proteins called HER2 and EGFR, which are involved in the growth of cancer cells. By inhibiting these proteins, Lapatinib helps to slow down or stop the proliferation of cancer cells. Patients typically take this medication once daily in combination with another anticancer drug. Please consult your healthcare provider for personalized medical advice before starting this treatment.
Tykerb (Lapatinib) dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 250MG | 150 Tablets | $2,045.33 | $13.64 |
Tykerb FAQs
Tykerb is used in combination with other medications to treat certain types of breast cancer, specifically HER2-positive breast cancer, in patients who have already received other cancer treatments.
Lapatinib may cause several side effects. Common side effects include diarrhea, nausea, vomiting, rash, and fatigue. Some patients may also experience hand-foot syndrome, decreased appetite, and mouth sores. Serious side effects can include liver problems, heart issues such as decreased heart function, and severe skin reactions. It is important for patients to report any unusual symptoms to their healthcare provider promptly.
Lapatinib can potentially cause heart-related side effects, including heart palpitations, although this is not very common. Patients experiencing heart palpitations while taking lapatinib should consult their healthcare provider for further evaluation and management.
The success rate of lapatinib can vary depending on the specific type and stage of cancer being treated, as well as individual patient factors. Lapatinib is often used in combination with other therapies for HER2-positive breast cancer. Clinical trials have shown that lapatinib, when used with other treatments, can improve progression-free survival and response rates in certain patients. However, it is important for patients to discuss their specific case with their healthcare provider to understand the potential benefits and success rates relevant to their situation.
Yes, diarrhea is a known side effect of Tykerb (lapatinib). It is important for patients experiencing this side effect to stay hydrated and consult their healthcare provider for appropriate management.